343 related articles for article (PubMed ID: 29713898)
1. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
Chang VY; Wang JJ
Curr Oncol Rep; 2018 Apr; 20(7):52. PubMed ID: 29713898
[TBL] [Abstract][Full Text] [Related]
2. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors.
Gündüz A; Duman D; Başbinar Y; Taşdelen B; Küpeli S; Karpuz D
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e65-e70. PubMed ID: 37828659
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Vargas-Neri JL; Carleton B; Ross CJ; Medeiros M; Castañeda-Hernández G; Clark P
Pharmacogenomics; 2022 Apr; 23(5):291-301. PubMed ID: 35147047
[No Abstract] [Full Text] [Related]
4. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
Aminkeng F; Ross CJ; Rassekh SR; Hwang S; Rieder MJ; Bhavsar AP; Smith A; Sanatani S; Gelmon KA; Bernstein D; Hayden MR; Amstutz U; Carleton BC;
Br J Clin Pharmacol; 2016 Sep; 82(3):683-95. PubMed ID: 27197003
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
[TBL] [Abstract][Full Text] [Related]
6. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T; Burmeister BT; Burridge PW
Pharmacol Ther; 2016 Dec; 168():113-125. PubMed ID: 27609196
[TBL] [Abstract][Full Text] [Related]
7. Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
Petrykey K; Andelfinger GU; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):865-883. PubMed ID: 32772754
[TBL] [Abstract][Full Text] [Related]
8. Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.
Christidi E; Huang H; Shafaattalab S; Maillet A; Lin E; Huang K; Laksman Z; Davis MK; Tibbits GF; Brunham LR
Sci Rep; 2020 Jun; 10(1):10363. PubMed ID: 32587261
[TBL] [Abstract][Full Text] [Related]
9. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity.
Siemens A; Rassekh SR; Ross CJD; Carleton BC
Ther Drug Monit; 2023 Jun; 45(3):337-344. PubMed ID: 36728273
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.
Linschoten M; Teske AJ; Cramer MJ; van der Wall E; Asselbergs FW
Circ Genom Precis Med; 2018 Jan; 11(1):e001753. PubMed ID: 29557343
[TBL] [Abstract][Full Text] [Related]
11. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.
Magdy T; Jiang Z; Jouni M; Fonoudi H; Lyra-Leite D; Jung G; Romero-Tejeda M; Kuo HH; Fetterman KA; Gharib M; Burmeister BT; Zhao M; Sapkota Y; Ross CJ; Carleton BC; Bernstein D; Burridge PW
Cell Stem Cell; 2021 Dec; 28(12):2076-2089.e7. PubMed ID: 34525346
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients.
Nyangwara VA; Mazhindu T; Chikwambi Z; Masimirembwa C; Campbell TB; Borok M; Ndlovu N
Br J Clin Pharmacol; 2023 Jan; ():. PubMed ID: 36630266
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.
Jensen BC; McLeod HL
Pharmacogenomics; 2013 Jan; 14(2):205-13. PubMed ID: 23327580
[TBL] [Abstract][Full Text] [Related]
14. Reducing anthracycline-induced cardiotoxicity through pharmacogenetics.
Scott E; Hasbullah JS; Ross CJ; Carleton BC
Pharmacogenomics; 2018 Oct; 19(15):1147-1150. PubMed ID: 30213233
[No Abstract] [Full Text] [Related]
15. Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.
Magdy T; Jouni M; Kuo HH; Weddle CJ; Lyra-Leite D; Fonoudi H; Romero-Tejeda M; Gharib M; Javed H; Fajardo G; Ross CJD; Carleton BC; Bernstein D; Burridge PW
Circulation; 2022 Jan; 145(4):279-294. PubMed ID: 34874743
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study.
Zolk O; von dem Knesebeck A; Graf N; Simon T; Hero B; Abdul-Khaliq H; Abd El Rahman M; Spix C; Mayer B; Elsner S; Gebauer J; Langer T
JMIR Res Protoc; 2022 Feb; 11(2):e27898. PubMed ID: 35175211
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.
Mihalcea DJ; Florescu M; Vinereanu D
Am J Ther; 2017; 24(1):e3-e11. PubMed ID: 27145188
[TBL] [Abstract][Full Text] [Related]
18. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR;
Pediatr Blood Cancer; 2013 Aug; 60(8):1375-81. PubMed ID: 23441093
[TBL] [Abstract][Full Text] [Related]
19. RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes.
Huang H; Christidi E; Shafaattalab S; Davis MK; Tibbits GF; Brunham LR
Stem Cell Reports; 2022 Apr; 17(4):756-765. PubMed ID: 35364012
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?
Hockings JK; Castrillon JA; Cheng F
Hum Mol Genet; 2020 Oct; 29(R2):R177-R185. PubMed ID: 32601683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]